Keep knowledgeable with free updates
Merely signal as much as the Non-public fairness myFT Digest — delivered on to your inbox.
One of many world’s largest laboratory tools suppliers has been put up on the market by its non-public fairness homeowners, as money generated from exits of sponsor-backed healthcare corporations approaches its highest stage since earlier than the pandemic.
Private equity teams GTCR and Golden Gate Capital have employed advisers from Goldman Sachs and Jefferies to run an public sale course of for Antylia Scientific, three individuals aware of the matter stated, including the sale may fetch greater than $2bn.
The money generated from non-public fairness exits of healthcare corporations has picked up this 12 months as companies look to return money to buyers, however deal depend stays low.
Monetary sponsors have generated practically $115bn from full or partial exits of healthcare corporations throughout 192 offers since January, in accordance with PitchBook knowledge. That has put 2024 on observe to surpass the $145bn generated in 2021, which might make it the most effective 12 months for capital returns from sponsor-backed healthcare exits in 5 years. However the variety of non-public fairness exits is about to be the bottom in no less than a decade.
The massive windfall from healthcare corporations is a vivid spot in an in any other case irritating marketplace for the non-public fairness business, which has struggled to return capital to buyers. Buyout teams personal greater than 28,000 portfolio corporations price a mixed $3.2tn, and plenty of have been reluctant to promote those who have did not generate the sorts of earnings that they had imagined, in accordance with consultancy Bain & Co.
The Antylia funding has already supplied wholesome returns to the 2 companies. In 2021, Antylia offered its Masterflex division, which specialises in pumps used for fluid switch through the manufacturing of monoclonal antibodies, vaccines and cell and gene therapies, to biotech group Avantor for $2.9bn.
GTCR first purchased Antylia, beforehand referred to as Cole-Parmer, from diagnostics group Thermo Fisher Scientific in 2014. It then offered Cole-Parmer to Golden Gate Capital in 2017 earlier than shopping for again a majority stake in 2019 for greater than $2bn. Golden Gate Capital retained a minority shareholding alongside Antylia’s administration group.
Antylia, which refinanced practically $1.75bn price of debt earlier this 12 months, now operates 5 manufacturers, the most important of which is Cole-Parmer Necessities, which provides greater than 200,000 various kinds of lab tools. The group additionally sells tools utilized in infectious ailments diagnostics and in wastewater evaluation.
Antylia is probably going to attract curiosity from diagnostic corporations in addition to different non-public fairness teams, the individuals stated.
GTCR, Golden Gate Capital, Goldman and Jefferies declined to remark.
Chicago-based GTCR was based in 1980 by Stanley Golder and Carl Thoma, two early and influential buyers within the buyout business.
Its leaders have largely targeted their efforts on midsized buyouts within the expertise, healthcare and financials industries, the place their robust returns have continued to draw buyers. Final 12 months GTCR raised $11.5bn for its flagship non-public fairness fund, eclipsing a $9.3bn goal and exceeding its earlier fund by greater than 40 per cent.
The agency, which manages $40bn, final 12 months struck one of many largest buyouts of 2023: the acquisition of a majority stake in Worldpay from FIS.
